Patents by Inventor James Haseloff
James Haseloff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6071730Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: June 6, 2000Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 6015794Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 6, 1995Date of Patent: January 18, 2000Assignee: The General Hospital CorporationInventors: James Haseloff, Howard M. Goodman
-
Patent number: 6010904Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: January 4, 2000Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5882907Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: March 16, 1999Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5874414Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.Type: GrantFiled: November 17, 1993Date of Patent: February 23, 1999Assignee: The General Hospital CorporationInventors: James Haseloff, Howard M. Goodman
-
Patent number: 5866384Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: February 2, 1999Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5863774Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: January 26, 1999Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5849548Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: June 7, 1995Date of Patent: December 15, 1998Assignees: The General Hospital Corporation, The President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
-
Patent number: 5641673Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are base a upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.Type: GrantFiled: December 23, 1993Date of Patent: June 24, 1997Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman